X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN LTD TORRENT PHARMA/
LUPIN LTD
 
P/E (TTM) x 37.2 161.7 23.0% View Chart
P/BV x 5.8 3.0 192.6% View Chart
Dividend Yield % 0.9 0.8 112.8%  

Financials

 TORRENT PHARMA   LUPIN LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
LUPIN LTD
Mar-17
TORRENT PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,750 101.0%   
Low Rs1,1861,384 85.7%   
Sales per share (Unadj.) Rs346.1387.4 89.3%  
Earnings per share (Unadj.) Rs55.256.6 97.4%  
Cash flow per share (Unadj.) Rs73.376.8 95.4%  
Dividends per share (Unadj.) Rs14.007.50 186.7%  
Dividend yield (eoy) %0.90.5 198.0%  
Book value per share (Unadj.) Rs257.1298.9 86.0%  
Shares outstanding (eoy) m169.22451.58 37.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.34.0 105.5%   
Avg P/E ratio x26.827.7 96.8%  
P/CF ratio (eoy) x20.120.4 98.8%  
Price / Book Value ratio x5.75.2 109.6%  
Dividend payout %25.413.2 191.6%   
Avg Mkt Cap Rs m249,887707,513 35.3%   
No. of employees `00011.816.8 70.2%   
Total wages/salary Rs m9,93428,495 34.9%   
Avg. sales/employee Rs Th4,971.510,418.3 47.7%   
Avg. wages/employee Rs Th843.21,697.0 49.7%   
Avg. net profit/employee Rs Th792.41,523.0 52.0%   
INCOME DATA
Net Sales Rs m58,569174,943 33.5%  
Other income Rs m2,2331,065 209.7%   
Total revenues Rs m60,802176,008 34.5%   
Gross profit Rs m13,77344,931 30.7%  
Depreciation Rs m3,0699,122 33.6%   
Interest Rs m2,0561,525 134.8%   
Profit before tax Rs m10,88135,349 30.8%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5459,785 15.8%   
Profit after tax Rs m9,33625,575 36.5%  
Gross profit margin %23.525.7 91.6%  
Effective tax rate %14.227.7 51.3%   
Net profit margin %15.914.6 109.0%  
BALANCE SHEET DATA
Current assets Rs m53,841119,542 45.0%   
Current liabilities Rs m31,61261,206 51.6%   
Net working cap to sales %38.033.3 113.8%  
Current ratio x1.72.0 87.2%  
Inventory Days Days9776 127.9%  
Debtors Days Days8490 93.2%  
Net fixed assets Rs m42,079131,660 32.0%   
Share capital Rs m846903 93.7%   
"Free" reserves Rs m42,655134,073 31.8%   
Net worth Rs m43,501134,976 32.2%   
Long term debt Rs m22,40856,478 39.7%   
Total assets Rs m101,250266,073 38.1%  
Interest coverage x6.324.2 26.0%   
Debt to equity ratio x0.50.4 123.1%  
Sales to assets ratio x0.60.7 88.0%   
Return on assets %11.310.2 110.5%  
Return on equity %21.518.9 113.3%  
Return on capital %19.619.3 101.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,06681,885 24.5%   
Fx outflow Rs m5,30421,506 24.7%   
Net fx Rs m14,76260,378 24.4%   
CASH FLOW
From Operations Rs m10,12741,148 24.6%  
From Investments Rs m-7,869-25,287 31.1%  
From Financial Activity Rs m-1,9184,332 -44.3%  
Net Cashflow Rs m21220,193 1.0%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jun 20, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS